CHDI Report: Day 2

CHDI Report: Day 2

Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD

Dr Ed WildFebruary 09, 2011

CHDI Report: Day 1

CHDI Report: Day 1

Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene

Dr Jeff CarrollFebruary 08, 2011

Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way

Anti-nausea drug helps cells with the HD mutation stay healthy in a surprising way

Anti-nausea drug meclizine protects cells with the HD mutation from death by reducing cellular energy production

Dr Jeff CarrollFebruary 04, 2011

HDBuzz takes your questions to the annual therapeutics meeting of CHDI

HDBuzz takes your questions to the annual therapeutics meeting of CHDI

HDBuzz visits Palm Springs to talk with CHDI about the latest HD research. Send us your questions!

Dr Ed WildJanuary 28, 2011

Welcome to HDBuzz

Welcome to HDBuzz

Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co

Dr Ed WildJanuary 18, 2011

Memantine in HD: dose is everything

Memantine in HD: dose is everything

Memantine, a drug already used in Alzheimer’s disease, might help in HD, but a mouse study shows dose is everything.

Dr Jeff CarrollJanuary 15, 2011

An active lifestyle may make a difference to HD symptoms

An active lifestyle may make a difference to HD symptoms

More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.

Deepti BabuJanuary 10, 2011

Frequently asked questions, January 2011

Frequently asked questions, January 2011

Answers to frequently-asked questions about HD – the first in a regular series of HDBuzz FAQ articles.

Dr Ed WildJanuary 07, 2011

Getting the data out – a new scientific journal just for HD

Getting the data out – a new scientific journal just for HD

New scientific journal PLoS Currents HD promises rapid publication & open access, improving scientific communication

Dr Michael OrthJanuary 04, 2011

Dimebon: disappointing in Alzheimer’s but might work in HD

Dimebon: disappointing in Alzheimer’s but might work in HD

Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.

Dr Jeff CarrollDecember 23, 2010

Focused drug screening leads to improved drugs to increase the rate of cellular recycling

Focused drug screening leads to improved drugs to increase the rate of cellular recycling

Advanced drug screening techniques help scientists to make drugs that increase cellular recycling in neurons.

Dr Jeff CarrollDecember 16, 2010